2024
1699P Impact of Latino ethnicity on the gut microbiome and response to immune checkpoint inhibition (ICI) with CBM588 in patients (pts) with metastatic renal cell cancer (mRCC)
Barragan-Carrillo R, Zengin Z, Dizman N, Ebrahimi H, Meza L, Jaime-Casas S, Li X, Dorff T, Hsu J, Salgia N, Chehrazi-Raffle A, Tripathi A, Castro D, Mercier B, Caporaso G, Lee K, Pal S. 1699P Impact of Latino ethnicity on the gut microbiome and response to immune checkpoint inhibition (ICI) with CBM588 in patients (pts) with metastatic renal cell cancer (mRCC). Annals Of Oncology 2024, 35: s1018. DOI: 10.1016/j.annonc.2024.08.1792.Peer-Reviewed Original ResearchPrevalence of Dietary Modification and Supplement Use in Patients with Metastatic Renal Cell Carcinoma Receiving Systemic Therapy
Ebrahimi H, Battle D, Salgia N, Zengin Z, Dizman N, Meza L, Bergerot C, Barragan-Carrillo R, Hsu J, Castro D, Mercier B, Chawla N, Li X, Tripathi A, Liu S, Chehrazi-Raffle A, Vaishampayan U, Staehler M, Pal S. Prevalence of Dietary Modification and Supplement Use in Patients with Metastatic Renal Cell Carcinoma Receiving Systemic Therapy. Nutrients 2024, 16: 1630. PMID: 38892563, PMCID: PMC11174627, DOI: 10.3390/nu16111630.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaRenal cell carcinomaCell carcinomaDietary modificationSupplement useDiagnosis of renal cell carcinomaFirst-line treatmentSupplement usageSystemic therapyCombination therapyAntineoplastic therapyKetogenic dietCarcinomaCancer therapyMediterranean dietPhysician-patient dialoguePatientsTherapyCancer treatmentGrowing body of evidenceBody of evidenceDietary changesCancerCancer diagnosisCannabidiolInfigratinib Versus Placebo for Patients with High-risk Resected Urothelial Cancer Bearing an FGFR3 Genomic Alteration: Results from the PROOF302 Phase 3 Trial
Pal S, Grivas P, Gupta S, Dizman N, Zengin Z, Valderrama B, Rodriguez-Vida A, Roghmann F, Sevillano Fernandez E, Matin S, Loriot Y, Sridhar S, Sonpavde G, Fleming M, Lerner S, Bellmunt J, Master V, Tripathi A, Davis K, van Veenhuyzen D, Weng R, Daneshmand S. Infigratinib Versus Placebo for Patients with High-risk Resected Urothelial Cancer Bearing an FGFR3 Genomic Alteration: Results from the PROOF302 Phase 3 Trial. European Urology 2024 PMID: 38580518, DOI: 10.1016/j.eururo.2024.03.023.Peer-Reviewed Original Research
2023
Association Between Time-of-Day of Immune Checkpoint Blockade Administration and Outcomes in Metastatic Renal Cell Carcinoma
Dizman N, Govindarajan A, Zengin Z, Meza L, Tripathi N, Sayegh N, Castro D, Chan E, Lee K, Prajapati S, Feng M, Loo V, Pace M, O'Brien S, Bailey E, Barragan-Carrillo R, Chehrazi-Raffle A, Hsu J, Li X, Agarwal N, Pal S. Association Between Time-of-Day of Immune Checkpoint Blockade Administration and Outcomes in Metastatic Renal Cell Carcinoma. Clinical Genitourinary Cancer 2023, 21: 530-536. PMID: 37495481, DOI: 10.1016/j.clgc.2023.06.004.Peer-Reviewed Original ResearchConceptsMetastatic renal cell carcinomaObjective response rateTreatment failureRenal cell carcinomaHazard ratioOverall survivalCell carcinomaMultivariate analysisHigh Cut-OffNivolumab/ipilimumabProspective Randomized StudyBaseline characteristicsRandomized studyClinical outcomesMedian timePreclinical evidenceUnivariate analysisPatientsResponse rateImmune systemInfusion timeStatistical significanceOutcomesCarcinomaInfusionChanges in Perception of Cure Among Patients With Genitourinary Cancers Initiating Immune Checkpoint Inhibitors: A Longitudinal Study
Bergerot C, Philip E, Govindarajan A, Castro D, Malhotra J, Bergerot P, Salgia S, Salgia M, Salgia N, Hsu J, Meza L, Zengin Z, Liu S, Chehrazi-Raffle A, Tripathi A, Dorff T, Pal S. Changes in Perception of Cure Among Patients With Genitourinary Cancers Initiating Immune Checkpoint Inhibitors: A Longitudinal Study. Clinical Genitourinary Cancer 2023, 21: 626-630.e3. PMID: 37391301, PMCID: PMC11225089, DOI: 10.1016/j.clgc.2023.05.018.Peer-Reviewed Original ResearchConceptsPerception of cureExpectation of cureGenitourinary cancersImmune checkpoint inhibitor therapyCheckpoint inhibitor therapyImmune checkpoint inhibitorsProportion of patientsSevere side effectsLongitudinal studyChi-square testICI therapyCheckpoint inhibitorsInhibitor therapyECOG scoreGeneral linear modelingPatients' perceptionsMetastatic cancerPatientsSide effectsDecreased anxietyTherapyCancerCureLower ratesAnxiety ScaleUltrasensitive Circulating Tumor DNA Pilot Study Distinguishes Complete Response and Partial Response With Immunotherapy in Patients With Metastatic Renal Cell Carcinoma
Chehrazi-Raffle A, Muddasani R, Dizman N, Hsu J, Meza L, Zengin Z, Malhotra J, Chawla N, Dorff T, Contente-Cuomo T, Dinwiddie D, McDonald B, McDaniel T, Trent J, Baehner F, Murtaza M, Pal S. Ultrasensitive Circulating Tumor DNA Pilot Study Distinguishes Complete Response and Partial Response With Immunotherapy in Patients With Metastatic Renal Cell Carcinoma. JCO Precision Oncology 2023, 7: e2200543. PMID: 37027813, PMCID: PMC10309555, DOI: 10.1200/po.22.00543.Peer-Reviewed Original ResearchConceptsMetastatic renal cell carcinomaPartial responseComplete responseVariant allele fractionRenal cell carcinomaCell carcinomaCtDNA analysisImmune checkpoint inhibitor therapyCheckpoint inhibitor therapyDiscontinuation of immunotherapyDepth of responseICI therapyNivolumab monotherapyEligible patientsRadiographic progressionInhibitor therapyPeripheral bloodDisease progressionCtDNA assessmentSubsequent progressionPatientsMultiple indicationsSingle time pointPatient-specific mutationsSecondary objectiveGenomic and Transcriptomic Predictors of Response from Stereotactic Body Radiation Therapy in Patients with Oligoprogressive Renal Cell Carcinoma
Zengin Z, Govindarajan A, Salgia N, Sayegh N, Tripathi N, Muddasani R, Chehrazi-Raffle A, Feng M, Mercier B, Ladbury C, Hao C, Salgia S, Chawla N, Meza L, Malhotra J, Dizman N, Hsu J, Castro D, Barragan-Carrillo R, Ebrahimi H, Philip E, Chang M, Zhang J, Byron S, Lyou Y, Dorff T, Pal S, Dandapani S. Genomic and Transcriptomic Predictors of Response from Stereotactic Body Radiation Therapy in Patients with Oligoprogressive Renal Cell Carcinoma. European Urology Oncology 2023, 6: 447-450. PMID: 36609061, DOI: 10.1016/j.euo.2022.11.006.Peer-Reviewed Original ResearchConceptsMetastatic renal cell carcinomaStereotactic body radiation therapyRenal cell carcinomaBody radiation therapyCell carcinomaRadiation therapyClear cell renal cell carcinomaFirst-line treatmentCell renal cell carcinomaStereotactic body radiotherapyKidney cancer patientsOligoprogressive diseaseSystemic treatmentReactive oxygen species pathwayBody radiotherapyCancer patientsTreatment selectionPatientsTreatment changesOxygen species pathwayRadiation treatmentCarcinomaCell proliferationPotential roleRadiotherapyPerceptions of COVID-19 Vaccination in Patients with Genitourinary Cancers: A Survey Study
Castro D, Zengin Z, Malhotra J, Bergerot C, Meza L, Dizman N, Govindarajan A, Hsu J, Chehrazi-Raffle A, Chawla N, Mercier B, Chen S, Feng M, Prajapati S, Lee K, Philip E, Dorff T, Lyou Y, Pal S. Perceptions of COVID-19 Vaccination in Patients with Genitourinary Cancers: A Survey Study. Cancer Investigation 2023, 41: 70-76. PMID: 36239609, DOI: 10.1080/07357907.2022.2136683.Peer-Reviewed Original Research
2022
880 Activation of STAT3 signaling is associated with resistance to immune checkpoint inhibitors in patients (pts) with metastatic renal cell carcinoma (mRCC)
Chehrazi-Raffle A, Alcantara M, Dizman N, Tang W, Meza L, Zengin Z, Wang D, Moreira D, Castro D, Govindarajan A, Horsager A, Hsu J, Pal S, Kortylewski M. 880 Activation of STAT3 signaling is associated with resistance to immune checkpoint inhibitors in patients (pts) with metastatic renal cell carcinoma (mRCC). 2022, a917-a917. DOI: 10.1136/jitc-2022-sitc2022.0880.Peer-Reviewed Original ResearchTemporal Characteristics of Adverse Events of Tivozanib and Sorafenib in Previously Treated Kidney Cancer
Zengin Z, Pal S, McDermott D, Escudier B, Hutson T, Porta C, Verzoni E, Atkins M, Kasturi V, Rini B. Temporal Characteristics of Adverse Events of Tivozanib and Sorafenib in Previously Treated Kidney Cancer. Clinical Genitourinary Cancer 2022, 20: 553-557. PMID: 36096984, DOI: 10.1016/j.clgc.2022.08.005.Peer-Reviewed Original ResearchConceptsMetastatic renal cell carcinomaRenal cell carcinomaDose modificationSorafenib armAdverse eventsCell carcinomaVascular endothelial growth factor receptor inhibitorEndothelial growth factor receptor inhibitorImproved progression-free survivalGrowth factor receptor inhibitorsProgression-free survivalDuration of toxicityMeasurable diseaseOpen labelFree survivalPrimary endpointTreatment discontinuationTreatment armsReceptor inhibitorsDose reductionKidney cancerTRAEsPatientsTivozanibSorafenibNivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial
Dizman N, Meza L, Bergerot P, Alcantara M, Dorff T, Lyou Y, Frankel P, Cui Y, Mira V, Llamas M, Hsu J, Zengin Z, Salgia N, Salgia S, Malhotra J, Chawla N, Chehrazi-Raffle A, Muddasani R, Gillece J, Reining L, Trent J, Takahashi M, Oka K, Higashi S, Kortylewski M, Highlander SK, Pal SK. Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial. Nature Medicine 2022, 28: 704-712. PMID: 35228755, PMCID: PMC9018425, DOI: 10.1038/s41591-022-01694-6.Peer-Reviewed Original ResearchConceptsMetastatic renal cell carcinomaProgression-free survivalRenal cell carcinomaCell carcinomaCheckpoint inhibitorsResponse rateGut microbiomePoor-risk diseaseTreatment-naive patientsSingle-center studyPhase 1 trialRandomized phase 1 trialSignificant differencesBifidobacterium sppMechanism of actionNivolumab-ipilimumabSarcomatoid histologyPrimary endpointSecondary endpointsImmune compartmentStudy armsClinical outcomesClear cellsClinical observationsPatientsCharacteristics associated with common reasons to pursue genomic profiling among patients with metastatic genitourinary cancers.
Malhotra J, Philip E, Govindarajan A, Salgia S, Meza L, Zengin Z, Muddasani R, Chawla N, Castro D, Chehrazi-Raffle A, Dizman N, Bergerot P, Hsu J, Dorff T, Pal S, Bergerot C. Characteristics associated with common reasons to pursue genomic profiling among patients with metastatic genitourinary cancers. Journal Of Clinical Oncology 2022, 40: 327-327. DOI: 10.1200/jco.2022.40.6_suppl.327.Peer-Reviewed Original ResearchPhysician indicationGenitourinary cancersTreatment responseCommon reasonAdvanced genitourinary cancersMetastatic genitourinary cancerGenomic profiling testsCross-sectional studyEffective provider communicationChart reviewOlder patientsPatient characteristicsYounger patientsClinicopathologic characteristicsPatients' perceptionsProvider communicationPatient responsePatientsOlder ageGenomic profilingLow levelsCancerImportant associationProfiling testsGPsChanges in perception of immunotherapy over time among patients with advanced genitourinary cancers.
Malhotra J, Philip E, Govindarajan A, Meza L, Zengin Z, Salgia S, Muddasani R, Chawla N, Castro D, Chehrazi-Raffle A, Dizman N, Bergerot P, Hsu J, Dorff T, Pal S, Bergerot C. Changes in perception of immunotherapy over time among patients with advanced genitourinary cancers. Journal Of Clinical Oncology 2022, 40: 328-328. DOI: 10.1200/jco.2022.40.6_suppl.328.Peer-Reviewed Original ResearchAdvanced genitourinary cancersGenitourinary cancersExpectation of cureQuality of lifeSide effectsMetastatic genitourinary cancerProportion of patientsStart of therapyMajority of patientsMonths of treatmentRenal cell carcinomaSevere side effectsLongitudinal studyMedian ageClinical outcomesImmunotherapy treatmentCell carcinomaPatients' perceptionsImmunotherapyPatientsGreater efficacyTumor progressionCancerCancer treatmentTime points
2021
1564MO Characterization of COVID-19 vaccination response by antibody (Ab) titer and T-cell receptor (TCR) sequencing in patients (pts) with advanced genitourinary (GU) cancers
Salgia S, Malhotra J, Zengin Z, Meza L, Ely J, Hsu J, Kelley E, Chehrazi-Raffle A, Govindarajan A, Muddasani R, Salgia N, Dizman N, Chawla N, Dorff T, Lyou Y, Karczewska E, Trent J, Salgia R, Altin J, Pal S. 1564MO Characterization of COVID-19 vaccination response by antibody (Ab) titer and T-cell receptor (TCR) sequencing in patients (pts) with advanced genitourinary (GU) cancers. Annals Of Oncology 2021, 32: s1132. PMCID: PMC8454399, DOI: 10.1016/j.annonc.2021.08.1557.Peer-Reviewed Original Research1759MO Associations between sarcopenia and gut microbiota in patients (pts) with metastatic renal cell carcinoma (mRCC) and breast cancer (BC)
Zengin Z, Malhotra J, Salgia S, Dizman N, Yost S, Chawla N, Govindarajan A, Hsu J, Salgia N, Bergerot P, Meza L, Chehrazi-Raffle A, Muddasani R, Gillece J, Yuan Y, Highlander S, Pal S. 1759MO Associations between sarcopenia and gut microbiota in patients (pts) with metastatic renal cell carcinoma (mRCC) and breast cancer (BC). Annals Of Oncology 2021, 32: s1211. DOI: 10.1016/j.annonc.2021.08.1704.Peer-Reviewed Original ResearchComplementary Role of Circulating Tumor DNA Assessment and Tissue Genomic Profiling in Metastatic Renal Cell Carcinoma
Zengin ZB, Weipert C, Salgia NJ, Dizman N, Hsu J, Meza L, Chehrazi-Raffle A, Muddasani R, Salgia S, Malhotra J, Chawla N, Philip EJ, Kiedrowski L, Maughan BL, Rathi N, Goel D, Choueiri TK, Agarwal N, Pal SK. Complementary Role of Circulating Tumor DNA Assessment and Tissue Genomic Profiling in Metastatic Renal Cell Carcinoma. Clinical Cancer Research 2021, 27: 4807-4813. PMID: 34130999, DOI: 10.1158/1078-0432.ccr-21-0572.Peer-Reviewed Original ResearchConceptsMetastatic renal cell carcinomaCell-free tumor DNARenal cell carcinomaGenomic profilingCell carcinomaTissue-based testingTumor DNA (ctDNA) assessmentClinical Laboratory Improvement AmendmentsActionable alterationsCtDNA profilingCtDNA assessmentPatientsTumor DNAUnique alterationsAlteration frequencyCarcinomaDNA assessmentBloodGreater temporal separationTissueAlterationsConcordancePrevious findingsMutationsConcordance analysisFirst assessment of the stool mycobiome in patients (pts) with metastatic renal cell carcinoma (mRCC) receiving targeted therapy (TT) or immunotherapy (IO).
Dizman N, Hsu J, Gillece J, Folkerts M, Reining L, Bergerot P, Meza L, Zengin Z, Muddasani R, Chawla N, Karimi M, Trent J, Highlander S, Pal S. First assessment of the stool mycobiome in patients (pts) with metastatic renal cell carcinoma (mRCC) receiving targeted therapy (TT) or immunotherapy (IO). Journal Of Clinical Oncology 2021, 39: 337-337. DOI: 10.1200/jco.2021.39.6_suppl.337.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaClinical benefitClear cell histologyMajority of ptsRenal cell carcinomaMedian relative abundanceCell histologyMetastatic diseaseClinical outcomesCell carcinomaDiscriminant analysis effect sizePancreatic cancerLinear discriminant analysis effect sizeImmunotherapyLarge seriesSerial samplesPotential associationFungal elementsPatientsMalassezia sppMultiple timepointsMicrobiome compositionTherapyEffect sizeAspergillus fumigatusIllustration of temporal evolution in patients with metastatic renal cell carcinoma (mRCC) using both circulating tumor DNA (ctDNA) and tissue-based genomic data.
Zengin Z, Weipert C, Hsu J, Salgia N, Hensel C, Maughan B, Rathi N, Goel D, Agarwal N, Choueiri T, Pal S. Illustration of temporal evolution in patients with metastatic renal cell carcinoma (mRCC) using both circulating tumor DNA (ctDNA) and tissue-based genomic data. Journal Of Clinical Oncology 2021, 39: 347-347. DOI: 10.1200/jco.2021.39.6_suppl.347.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaGenomic profilingCtDNA alterationsMost common histologySubset of ptsRenal cell carcinomaSeparate validation cohortTissue-based assessmentProportion of alterationsCommon histologyMedian timeValidation cohortCell carcinomaCtDNA assessmentClear cellsCtDNA analysisTumor DNACohortGene panelTissue samplesTissue assessmentMonthsOnly alterationSignificant differencesPatients
2020
Assessment of circulating cell-free tumor DNA (ctDNA) in 847 patients (pts) with metastatic renal cell carcinoma (mRCC) and concordance with tissue-based testing
Zengin Z, Weipert C, Hsu J, Salgia N, Saam J, Choueiri T, Agarwal N, Pal S. Assessment of circulating cell-free tumor DNA (ctDNA) in 847 patients (pts) with metastatic renal cell carcinoma (mRCC) and concordance with tissue-based testing. Annals Of Oncology 2020, 31: s553-s554. DOI: 10.1016/j.annonc.2020.08.773.Peer-Reviewed Original Research
2019
Is Cd11c and Fmc7 Negativity in Chronic Lymphocytic Leukemia Poor Prognostic?
Şentürk Yikilmaz A, Akinci S, Bakanay Ş, Zengin Z, Dilek İ. Is Cd11c and Fmc7 Negativity in Chronic Lymphocytic Leukemia Poor Prognostic? Indian Journal Of Hematology And Blood Transfusion 2019, 36: 84-90. PMID: 32158089, PMCID: PMC7042443, DOI: 10.1007/s12288-019-01169-8.Peer-Reviewed Original ResearchChronic lymphocytic leukemiaNegative patient groupPatient groupFirst-line treatmentRisk of progressionTime of diagnosisPositive patient groupCommon hematological malignancyPoor prognostic markerStep treatmentStable diseaseProgressive diseaseCytometric findingsPrognostic effectCLL treatmentPoor prognosticCLL patientsPrognostic markerLymphocytic leukemiaHematological malignanciesGroup 2Group 1PatientsTotal survivalSecond-step treatment